|
Investor Relations
ApoImmune, Inc. is a biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the host immune system to fight disease. We are building both drug discovery and clinical development capabilities that can support various research and development projects. Currently, we are concentrating our clinical capabilities on cancer as we start our first Phase I clinical trial. Our other research programs include infectious diseases, Type 1 diabetes, and cell/organ transplantation.
To receive investor information, please contact:
Steven Downey
President and CEO
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493
sdowney[at]apoimmune.com
|
|
|
